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Abstract
Nasopharyngeal carcinoma (NPC) is a tumor arising from the epithelial cells that cover the surface
and line the nasopharynx. The annual incidence of NPC in the UK is 0.3 per million at age 0–14
years, and 1 to 2 per million at age 15–19 years. Incidence is higher in the Chinese and Tunisian
populations. Although rare, NPC accounts for about one third of childhood nasopharyngeal
neoplasms. Three subtypes of NPC are recognized in the World Health Organization (WHO)
classification: 1) squamous cell carcinoma, typically found in the older adult population; 2) non-
keratinizing carcinoma; 3) undifferentiated carcinoma. The tumor can extend within or out of the
nasopharynx to the other lateral wall and/or posterosuperiorly to the base of the skull or the
palate, nasal cavity or oropharynx. It then typically metastases to cervical lymph nodes. Cervical
lymphadenopathy is the initial presentation in many patients, and the diagnosis of NPC is often
made by lymph node biopsy. Symptoms related to the primary tumor include trismus, pain, otitis
media, nasal regurgitation due to paresis of the soft palate, hearing loss and cranial nerve palsies.
Larger growths may produce nasal obstruction or bleeding and a "nasal twang". Etiological factors
include Epstein-Barr virus (EBV), genetic susceptibility and consumption of food with possible
carcinogens – volatile nitrosamines. The recommended treatment schedule consists of three
courses of neoadjuvant chemotherapy, irradiation, and adjuvant interferon (IFN)-beta therapy.
Definition
Nasopharyngeal carcinoma (NPC) is a tumor arising from
the epithelial cells that cover the surface and line the
nasopharynx. NPC was first described as a separate entity
by Regaud and Schmincke in 1921 [1,2]. Approximately
one third of nasopharyngeal carcinomas of the undiffer-
entiated type are diagnosed in adolescents or young
adults. Although rare, NPC accounts for one third of
childhood nasopharyngeal neoplasms (data from USA)
[3].
Epidemiology
The annual incidence of NPC in the UK is 0.25 per million
(age standardized, age 0–14 years), 0.1 per million at age
0–9 years and 0.8 per million at age 10–14 years. It seems
reasonable to assume, on the basis of England and Wales
cancer registry data, that at least 80% of nasopharyngeal
cancers at age 15–19 years are carcinomas. This suggests
an incidence of 1 to 2 per million for NPC at age 15–19
years.
In comparison with other countries, the incidence in the
UK is low. In particular, in Tunisia the incidence is rela-
tively high [4]. In southern parts of China, Southeast Asia,
the Mediterranean basin and Alaska the incidence of NPC
is moderately elevated; an incidence of 2 per million of
NPC in China has been reported [5]. In other countries,
for example in India, the incidence is comparable to that
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peak in the second decade found in India [6], is also
found in the UK [7].
Etiology
NPC is the commonest epithelial cancer in adults. The
detection of nuclear antigen associated with Epstein-Barr
virus (EBNA) and viral DNA in NPC type 2 and 3, has
revealed that EBV can infect epithelial cells and is associ-
ated with their transformation [8]. The etiology of NPC
(particularly the endemic form) seems to follow a multi-
step process, in which EBV, ethnic background, and envi-
ronmental carcinogens all seem to play an important role.
Lo et al. showed that EBV DNA was detectable in the
plasma samples of 96% of patients with non-keratinizing
NPC, compared with only 7% in controls [9]. More
importantly, EBV DNA levels appear to correlate with
treatment response [9-11] and they may predict disease
recurrence [11], suggesting that they may be an independ-
ent indicator of prognosis [12].
In adults, other likely etiological factors include genetic
susceptibility, consumption of food (in particular salted
fish) containing carcinogenic volatile nitrosamines, and
as in children, EBV [13,15-19].
Clinical presentation
NPC usually originates in the lateral wall of the nasophar-
ynx, which includes the fossa of Rosenmuller. It can then
extend within or out of the nasopharynx to the other lat-
eral wall and/or posterosuperiorly to the base of the skull
or the palate, nasal cavity or oropharynx. It then typically
metastases to cervical lymph nodes. Distant metastases
may occur in bone, lung, mediastinum and, more rarely,
the liver.
Cervical lymphadenopathy is the initial presentation in
many patients, and the diagnosis of NPC is often made by
lymph node biopsy. Symptoms related to the primary
tumor include trismus, pain, otitis media, nasal regurgita-
tion due to paresis of the soft palate, hearing loss and cra-
nial nerve palsies. Larger growths may produce nasal
obstruction or bleeding and a "nasal twang". Metastatic
spread may result in bone pain or organ dysfunction.
Rarely, a paraneoplastic syndrome of osteoarthropathy
may occur with widespread disease.
Histopathology
Three subtypes of NPC are recognized in the World Health
Organisation (WHO) classification [20]:
• type 1: squamous cell carcinoma, typically found in the
older adult population
• type 2: non-keratinizing carcinoma
• type 3: undifferentiated carcinoma
Most cases in childhood and adolescence are type 3, with
a few type 2 cases [21]. Type 2 and 3 are associated with
elevated Epstein-Barr virus titers, but type 1 is not [22].
The Cologne modification of the WHO scheme by
Krueger and Wustrow [23] includes the degree of lym-
phoid infiltration. Types 2 and 3 may be accompanied by
an inflammatory infiltrate of lymphocytes, plasma cells,
and eosinophils, which are abundant, giving rise to the
term lymphoepithelioma. Two histological patterns may
occur: Regaud type, with a well-defined collection of epi-
thelial cells surrounded by lymphocytes and connective
tissue, and Schmincke type, in which the tumor cells are
distributed diffusely and intermingle with the inflamma-




1. Clinical evaluation of the size and location of cervical
lymph nodes.
2. Indirect nasopharyngoscopy to assess the primary
tumor.
3. Neurological examination of cranial nerves.
4. Computed tomography (CT)/magnetic resonance
imaging (MRI) scan of the head and neck to below clavi-
cles to assess base of skull erosion.
5. Chest radiotherapy (anteroposterior and lateral) to see
if NPC has spread to the lungs.
6. Bone scintigraphy by Tc 99 diphosphonate to show
whether cancer has spread to the bones.
7. Full blood count.
8. Urea, electrolyte, creatinine, liver function, Ca, PO4,
alkaline phosphate.
9. EBV viral capsid antigen and EBV DNA.
10. Biopsy of either the lymph nodes or primary tumor for
histological examination.
Staging
The tumor, node, metastasis (TNM) classification of the
American Joint Committee on Cancer [24] – sixth edition
(Table 1) is usually used to determine the tumor stagingPage 2 of 5
(page number not for citation purposes)
Orphanet Journal of Rare Diseases 2006, 1:23 http://www.OJRD.com/content/1/1/23(Table 2). This latest TNM classification takes into account
Ho's [25] modifications for NPC, which utilizes the prog-
nostic importance of affected nodes extending into the
lower cervical and supraclavicular areas.
Treatment
Surgery
Due to the anatomical position of NPC and its tendency
to present with cervical lymph node metastases, it is not
amenable to surgery for local control. Biopsy of the
involved lymph node is the usual surgical procedure. The
nasopharyngeal primary tumor is rarely biopsied.
Chemotherapy
Several factors are taken into account in deciding the
chemotherapy regimen.
Firstly, efficacy: the figures for event-free survival are sim-
ilar for most small chemotherapy series but therapy usu-
ally involves fairly high-dose radiotherapy to the
nasopharynx – 60 to 65 Gy. However, the most promising
results with a recent update, are those obtained using the
Mertens protocol NPC-91-GPOH (Society of Pediatric
Oncology and Hematology). This protocol should there-
fore be considered as the best current treatment.
Uniquely, the NPC-91-GPOH protocol includes immu-
notherapy with interferon-beta after chemotherapy and
Table 1: The tumor, node, metastasis (TNM) classification of the American Joint Committee on Cancer [24]
Primary Tumor (T)
TX Primary tumor cannot be assessed
TO No evidence of primary tumor
Tis Carcinoma in situ
Nasopharynx
T1 Tumor confined to the nasopharynx
T2 Tumor extends to soft tissues of oropharynx and/or nasal fossa
• T2a • without parapharyngeal extension
• T2b • with parapharyngeal extension
T3 Tumor invades bony structures and/or paranasal sinuses
T4 Tumor with intracranial extension and/or involvement of cranial nerves, 
infratemporal fossa, hypopharynx, or orbit, or masticator space
Regional Lymph Nodes (N): Nasopharynx
The distribution of regional lymph node spread from nasopharyngeal cancer, particularly of the undifferentiated type, is different than that of other 
head and neck mucosal cancers and justifies use of a different N classification scheme. In children this does not have a prognostic impact.
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Unilateral metastasis in lymph node(s), 6 cm or less in greatest 
dimension, above the supraclavicular fossa.
N2 Bilateral metastasis in lymph node (s) 6 cm or less in greatest dimension, 
above the supraclavicular fossa
N3 Metastasis in a lymph node(s)
• N3a • greater than 6 cm in dimension
• N3b • extension to the supraclavicular fossa
Distant Metastasis (M)
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
Table 2: Stage grouping
Stage 0 Tis N0 M0
Stage 1 T1 N0 M0
Stage IIA T2a N0 M0








Stage IVA T4 N0 M0
T4 N1 M0
T4 N2 M0
Stage IVB Any T N3 M0
Stage IVC Any T Any N M1Page 3 of 5
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pared to regimens without interferon treatment [27].
Secondly, late effects: in terms of chemotherapy, the Man-
chester regimen – doxorubicin, methotrexate and cyclo-
phosphamide – would produce infertility in boys (total
dose of cyclophosphamide 12 gm/m2) and possible
anthracycline toxicity (total dose of doxorubicin 360 mg/
m2) [36]. The NPC-91-GPOH protocol might produce
some infertility in older boys but the total dose of cisplat-
inum is only 300 mg/m2. Furthermore, the incidence of
renal toxicity should be relatively low but auditory toxic-
ity would be higher because of the additional effect of irra-
diation on the auditory apparatus. The degree of pituitary
dysfunction obviously depends on the radiotherapy field
and, potentially, on the dose of radiotherapy but some
degree of hypopituitarism is expected. Furthermore, irra-
diation to the neck would result in hypothyroidism for
the majority of patients and irradiation to the oropharynx
would result in xerostomia and resultant poor dentition.
The later may be relieved by amifostine, as demonstrated
in adult studies.
Radiotherapy
Although treatment with radiotherapy controls the pri-
mary tumor [28-30], it does not prevent the appearance of
distant metastases [28,31].
Radiotherapy is given with megavoltage equipment after
initial chemotherapy. A maximum dose of 45 Gy is given
to the clinical target volume, which is a 1 cm margin
around the MRI-detected primary site, and inferiorly
down to the clavicles to include the lymph nodes. Treat-
ment is given in two phases:
• Phase I – parallel pair (mostly lateral unless the tumor
extends anteriorly between the eyes). Eyes, brain and
brain stem are shielded as much as possible. A mid-plane
dose of 30 Gy in 15 fractions is given.
• Phase II – a lateral parallel pair or three-fields technique
is used for the primary site, delivering 15 Gy in seven frac-
tions to the clinical target volume of the tumor with a 1
cm margin. Brain stem and eyes should be shielded. Any
overlap with the neck field should be shielded. A match-
ing anterior neck node field is used to deliver a prescribed
maximum subcutaneous dose of 15 Gy in seven fractions.
The spinal cord should be shielded in this field. This pre-
scription for radiotherapy is used in Manchester, but it is
recognized that higher doses may be used in some centers,
possibly to a total of 60 Gy to the tumor volume. In an
current GPOH study, patients in complete remission (CR)
after three courses of chemotherapy, will have their radio-
therapy dosage reduced to 54 Gy instead of 59 Gy.
Recommendation
In the current GPOH protocol NPC-2003-GPOH, low-risk
patients with Stage I and II tumors receive radiotherapy
only, followed by 105 μg/Kg of adjuvant interferon beta
(IFNbeta), intravenously (i.v.), three times a week for 6
months. High-risk patients receive cisplatinum (100 mg/
m2 over 6 hours on day 1 with standard hydration), man-
nitol and electrolyte replacement, and folinic acid (25
mg/m2 every 6 hours for a total of six doses) as well as 5-
fluorouracil (1000 mg/m2 per day from day 2 for 5 days)
as a continuous infusion. They receive three courses of
chemotherapy every 21 days or on full blood count recov-
ery, followed by irradiation and IFNbeta as for low-risk
patients. Methotrexate has been dropped because of
severe mucositis. Patients not in CR after three courses of
chemotherapy will receive concomitant cisplatinum (20
mg/m2/day for 3 days with radiotherapy for two courses).
Prognostic factors
Presentation with lymphadenomegalia implies that the
disease has spread beyond the primary site. However, in
childhood the presence of metastatic disease in cervical
lymph nodes at diagnosis does not adversely affect prog-
nosis [30-33]. Factors associated with a poor prognosis are
skull base involvement [33-35], extent of the primary
tumor [31,32] and cranial nerve involvement [33,34].
Unresolved questions
1. What is the optimum radiotherapy dose?
2. Would exclusion of interferon from the treatment pro-
duce similar results?
3. The relationship between late effects and dose of radio-
therapy should be investigated, as well as the exact nature
and incidence of late effects.
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